The prognostic significance of circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide and neuron- specific enolase in patients with advanced non-small-cell lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Neuron-specific enolase (NSE) serum level as a prognostic factor for tumor regression and survival in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Clinical correlates and prognostic significance of neuron specific enolase (NSE) in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002
Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007
Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002
The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 78s Year: 2005
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009
Serum napsin A as a tumor marker for primary lung adenocarcinoma Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Serum carcinoembryonic antigen (CEA) level as a predictive marker for distant metastasis in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Role of progestrin releasing peptide (ProGRP), a serum based biomarker in early diagnosis of SCLC in cohort of high-risk patient presenting with symptoms related to lung cancer Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Procalitonin: A prognosis factor in lung cancer and a marker for small-cell lung cancer Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010
Usefulness of determination of tumour markers TPA and cyfra 21.1 in follow up study after radical therapy in patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001
Circulating free DNA, new dynamic marker in nonsmall cell lung cancer patients? Source: Eur Respir J 2015; 46: 1548-1550 Year: 2015
Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008
C-reactive protein and assessment of chemotherapy response in advanced non-small cell lung cancer Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017
The expression of Ki-67, a marker of proliferative activity, in resected nonsmall cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 478s Year: 2001
Prognostic significance of S-100 immmunostaining in non-small cell lung cancer (NSCLC) Source: Annual Congress 2004 - Prognostic factors Year: 2004
Clinical significance of serum cathepsin K level during chemotherapy of lung cancer. Can we use it as a marker of small cell lung cancer? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008